Project Description

Aruna Bio
Transforming Treatment for 12 Million People

Date & Time:

January 29, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Treating Alzheimer’s, Parkinson’s Disease, Multiple Sclerosis, Strokes and other neurodegenerative diseases has had one major hurdle: delivering targeted therapies into the brain.

Aruna Bio has solved that problem with an innovative payload delivery system that’s designed to cross the Blood/Brain Barrier naturally. Using exosomes from neural stem cells as a transporter, Aruna’s platform technology can deliver specialized therapeutics directly to the site of action.

Aruna Bio is poised to transform treatment for over 12 million patients with:
  • Partnerships with global pharmaceutical leaders
  • A dedicated manufacturing facility to ensure availability
  • A team of industry veterans leading the commercialization effort
  • A pipeline of therapeutic and delivery applications to treat a wide range of neurodegenerative diseases

Please join us to hear from CEO, Mark Sirgo and Co-founder, Steven Stice, PhD to learn how Aruna Bio is ready to make great strides in the treatment of these devastating diseases.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.